All products featured on GQ are independently selected by GQ editors. However, when you buy something through our retail links, Condé Nast may earn an affiliate commission. For more savings ...
Proceeds from the financing will support the advancement of three first- and best-in-class ADC programs through upcoming key clinical milestones While oncology continues to face substantial and ...
Kalohexis' lead programs include 710GO, an oral dual melanocortin-3 and-4 receptor (MC3R/MC4R) agonist, a next-generation general obesity treatment; and mifomelatide, a dual MC3R/MC4R antagonist to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results